Patents Assigned to Lycera Corporation
  • Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of RORy and the treatment of disease
    Patent number: 9802958
    Abstract: The invention provides tetrahydro[1,8]naphthyridine and related compounds, pharmaceutical compositions, methods of promoting ROR? activity, increasing the amount of IL-17 in a subject, and treating cancer using such tetrahydro[1,8]naphthyridine and related compounds.
    Type: Grant
    Filed: July 8, 2016
    Date of Patent: October 31, 2017
    Assignee: LYCERA CORPORATION
    Inventors: Thomas D. Aicher, Peter L. Toogood, Xiao Hu
  • Carbamate benzoxazine propionic acids and acid derivatives for modulation of RORgamma activity and the treatment of disease
    Patent number: 9783511
    Abstract: The invention provides certain benzoxazine compounds of the Formula (I) or pharmaceutically acceptable salts thereof wherein R1, R2, Ra1, Ra2, Rb1, Rb2, Rc, Rd, and Cy are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds of the Formula (I) or pharmaceutically acceptable salts thereof, and methods of using the compounds of the Formula (I) or pharmaceutically acceptable salts thereof or pharmaceutical compositions comprising the same for treating diseases or conditions mediated by RORgammaT.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: October 10, 2017
    Assignees: Lycera Corporation, Merck Sharp & Dohme Corp.
    Inventors: Thomas D. Aicher, Chad A. VanHuis, John MacLean, Brian M. Andresen, Kenneth J. Barr, Corey Bienstock, Matthew Daniels, Kun Liu, Yuan Liu, Catherine White, Nunzio Sciammetta, Vladimir Simov
  • Trifluoromethyl pyrazolyl guanidine FF-ATPase inhibitors and therapeutic uses thereof
    Patent number: 9707211
    Abstract: The invention provides trifluoromethyl pyrazolyl guanidine compounds that inhibit F1F0-ATPase, and methods of using trifluoromethyl pyrazolyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.
    Type: Grant
    Filed: February 4, 2016
    Date of Patent: July 18, 2017
    Assignee: Lycera Corporation
    Inventors: Alexander R. Hurd, Clarke B. Taylor, Jian Wang, Peng Zhou
  • 2-Acylamidomethyl and sulfonylamidomethyl benzoxazine carbamates for inhibition of RORgamma activity and the treatment of disease
    Patent number: 9663502
    Abstract: The invention provides certain benzoxazine compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein R1, R2, Ra, Rb, Rc, Rd, Rg, and Cy are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds of the Formula (I) or pharmaceutically acceptable salts thereof, and methods of using the compounds of the Formula (I) or pharmaceutically acceptable salts thereof or pharmaceutical compositions comprising the same for treating diseases or conditions mediated by RORgammaT.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: May 30, 2017
    Assignees: Lycera Corporation, Merck Sharp & Dohme Corp.
    Inventors: Thomas D. Aicher, Chad A. VanHuis, John MacLean, Brian M. Andresen, Kenneth J. Barr, Corey Bienstock, Neville J. Anthony, Matthew Daniels, Yuan Liu, Catherine White, Blair T. Lapointe, Nunzio Sciammetta, Vladimir Simov, Wesley B. Trotter, Kun Liu
  • Tetrahydronaphthyridine and related bicyclic compounds for inhibition of ROR? activity and the treatment of disease
    Patent number: 9657033
    Abstract: The invention provides tetrahydronaphthyridine and related compounds, pharmaceutical compositions, methods of inhibiting ROR? activity, reducing the amount of IL-17 in a subject, and treating immune disorders and inflammatory disorders using such tetrahydronaphthyridine and related compounds.
    Type: Grant
    Filed: May 7, 2013
    Date of Patent: May 23, 2017
    Assignees: Lycera Corporation, Merck Sharp & Dohme Corp.
    Inventors: Thomas D. Aicher, Kenneth J. Barr, Blair T. Lapointe, Vladimir Simov, Karin A. Stein, William D. Thomas, Peter L. Toogood, Chad A. Van Huis, Catherine M. White
  • Saturated acyl guanidine for inhibition of FF-ATPase
    Patent number: 9580391
    Abstract: The invention provides saturated acyl guanidine compounds that inhibit F1F0-ATPase, and methods of using saturated acyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.
    Type: Grant
    Filed: June 7, 2013
    Date of Patent: February 28, 2017
    Assignee: Lycera Corporation
    Inventors: Alexander R. Hurd, Clarke B. Taylor, Peter L. Toogood, Chad A. Van Huis
  • Pyrazolyl guanidine FF-ATPase inhibitors and therapeutic uses thereof
    Patent number: 9580388
    Abstract: The invention provides pyrazolyl guanidine compounds that inhibit F1Fo-ATPase, and methods of using pyrazolyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.
    Type: Grant
    Filed: July 16, 2015
    Date of Patent: February 28, 2017
    Assignee: Lycera Corporation
    Inventors: Gary D. Glick, Alexander R. Hurd, Clarke B. Taylor, Chad A. VanHuis
  • N-sulfonylated tetrahydroquinolines and related bicyclic compounds for inhibition of ROR? activity and the treatment of disease
    Patent number: 9512111
    Abstract: The invention provides tetrahydroquinoline and related compounds, pharmaceutical compositions, methods of inhibiting ROR? activity, reducing the amount of IL-17 in a subject, and treating immune disorders and inflammatory disorders using such tetrahydroquinoline and related compounds are provided.
    Type: Grant
    Filed: November 8, 2011
    Date of Patent: December 6, 2016
    Assignee: Lycera Corporation
    Inventors: Gary D. Glick, Peter L. Toogood, Arthur G. Romero, Chad A. Van Huis, Thomas D. Aicher, Carl Kaub, Matthew N. Mattson, William D. Thomas, Karin A. Stein, Erik Krogh-Jespersen, Zhan Wang
  • Tetrahydro[1,8]naphthyridine sulfonamide and related compounds for use as agonists of ROR? and the treatment of disease
    Patent number: 9394315
    Abstract: The invention provides tetrahydro[1,8]naphthyridine and related compounds, pharmaceutical compositions, methods of promoting ROR? activity, increasing the amount of IL-17 in a subject, and treating cancer, bacterial infections, and fungal infections using such tetrahydro[1,8]naphthyridine and related compounds.
    Type: Grant
    Filed: May 8, 2013
    Date of Patent: July 19, 2016
    Assignee: Lycera Corporation
    Inventors: Thomas D. Aicher, Peter L. Toogood, Xiao Hu
  • Pyridonyl guanidine FF-ATPase inhibitors and therapeutic uses thereof
    Patent number: 9370507
    Abstract: The invention provides pyridonyl guanidine compounds that inhibit F1F0-ATPase, and methods of using pyridonyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.
    Type: Grant
    Filed: April 1, 2015
    Date of Patent: June 21, 2016
    Assignee: Lycera Corporation
    Inventors: Gary D. Glick, Alexander R. Hurd, Matthew N. Mattson, Clarke B. Taylor, Chad A. Van Huis
  • Trifluoromethyl pyrazolyl guanidine FF-ATPase inhibitors and therapeutic uses thereof
    Patent number: 9266839
    Abstract: The invention provides trifluoromethyl pyrazolyl guanidine compounds that inhibit F1F0-ATPase, and methods of using trifluoromethyl pyrazolyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.
    Type: Grant
    Filed: December 10, 2014
    Date of Patent: February 23, 2016
    Assignee: Lycera Corporation
    Inventors: Alexander R. Hurd, Clarke B. Taylor, Jian Wang, Peng Zhou
  • Bicyclic sulfone compounds for inhibition of RORgamma activity and the treatment of disease
    Patent number: 9266827
    Abstract: The invention provides bicyclic sulfone compounds, pharmaceutical compositions, methods of inhibiting RORy activity, reducing the amount of iL-17 in a subject, and treating immune disorders and inflammatory disorders using such bicyclic sulfone compounds. Another aspect of the invention provides a method of treating a subject suffering from a medical disorder. The method comprises administering to the subject a therapeutically effective amount of one or more bicyclic sulfone compounds described herein. In certain other embodiments, the disorder is rheumatoid arthritis.
    Type: Grant
    Filed: May 3, 2013
    Date of Patent: February 23, 2016
    Assignees: Merck Sharp & Dohme Corp., Lycera Corporation
    Inventors: Thomas D. Aicher, Kenneth Jay Barr, Vladimir Simov, William D. Thomas, Peter L. Toogood, Chad A. Van Huis
  • Heterocyclic guanidine FF-atpase inhibitors and therapeutic uses thereof
    Patent number: 9221814
    Abstract: The invention provides heterocyclic guanidine compounds that inhibit F1F0-ATPase, and methods of using heterocyclic guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.
    Type: Grant
    Filed: June 7, 2013
    Date of Patent: December 29, 2015
    Assignee: Lycera Corporation
    Inventors: Alexander R. Hurd, Clarke B. Taylor, Peter L. Toogood
  • Cycloalkyl guanidine FF-ATPase inhibitors and therapeutic uses thereof
    Patent number: 9169199
    Abstract: The invention provides cycloalkyl guanidine compounds that inhibit F1F0-ATPase, and methods of using cyclalkyl guanidine compounds as therapeutic agents in therapy, such as treating an immune disorder, inflammatory condition, or cancer.
    Type: Grant
    Filed: December 8, 2011
    Date of Patent: October 27, 2015
    Assignee: Lycera Corporation
    Inventors: Alexander R. Hurd, Clarke B. Taylor, Peter L. Toogood, Chad A. Van Huis
  • Pyrazolyl guanidine FF-atpase inhibitors and therapeutic uses thereof
    Patent number: 9139532
    Abstract: The invention provides pyrazolyl guanidine compounds that inhibit F1Fo-ATPase, and methods of using pyrazolyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.
    Type: Grant
    Filed: December 8, 2011
    Date of Patent: September 22, 2015
    Assignee: Lycera Corporation
    Inventors: Gary D. Glick, Alexander R. Hurd, Clarke B. Taylor, Chad A. Van Huis
  • TRIFLUOROMETHYL PYRAZOLYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF
    Publication number: 20150183745
    Abstract: The invention provides trifluoromethyl pyrazolyl guanidine compounds that inhibit F1F0-ATPase, and methods of using trifluoromethyl pyrazolyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.
    Type: Application
    Filed: December 10, 2014
    Publication date: July 2, 2015
    Applicant: LYCERA CORPORATION
    Inventors: Alexander R. Hurd, Clarke B. Taylor, Jian Wang, Peng Zhou
  • Pyridonyl guanidine FF-ATPase inhibitors and therapeutic uses thereof
    Patent number: 9000014
    Abstract: The invention provides pyridonyl guanidine compounds that inhibit F1F0-ATPase, and methods of using pyridonyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.
    Type: Grant
    Filed: December 8, 2011
    Date of Patent: April 7, 2015
    Assignee: Lycera Corporation
    Inventors: Gary D. Glick, Alexander R. Hurd, Matthew N. Mattson, Clarke B. Taylor, Chad A. Van Huis
  • METHODS AND COMPOSITIONS FOR DETECTING IMMUNE SYSTEM ACTIVATION
    Publication number: 20150031068
    Abstract: The present invention relates to methods and compositions for detecting immune system activation and/or the presence of an immune disorder in a patient. More particularly, methods and compositions for detecting immune system activation and/or the presence of an immune disorder in a patient by detecting, for example, the concentration of certain metabolites of 13C-labeled glutamine, 13C-labeled palmitate, and/or 13C-labeled glucose.
    Type: Application
    Filed: March 15, 2013
    Publication date: January 29, 2015
    Applicant: Lycera Corporation
    Inventors: Gary D. Glick, Anthony W. Opipari, JR., Laszlo G. Boros
  • N-SULFONYLATED TETRAHYDROQUINOLINES AND RELATED BICYCLIC COMPOUNDS FOR INHIBITION OF RORgamma ACTIVITY AND THE TREATMENT OF DISEASE
    Publication number: 20140088094
    Abstract: The invention provides tetrahydroquinoline and related compounds, pharmaceutical compositions, methods of inhibiting ROR? activity, reducing the amount of IL-17 in a subject, and treating immune disorders and inflammatory disorders using such tetrahydroquinoline and related compounds are provided.
    Type: Application
    Filed: November 8, 2011
    Publication date: March 27, 2014
    Applicants: Merck Sharp & Dohme Corp., Lycera Corporation
    Inventors: Gary D. Glick, Peter L. Toogood, Arthur Glenn Romero, Chad A. Van Huis, Thomas Daniel Aicher, Carl Kaub, Matthew N. Mattson, William David Thomas, Karin Ann Sttein, Erik Krogh-Jespersen, Zhan Wang
  • PYRIDONYL GUANIDINE F1F0-ATPASE INHIBITORS AND THERAPEUTIC USES THEREOF
    Publication number: 20140051727
    Abstract: The invention provides pyridonyl guanidine compounds that inhibit F1F0-ATPase, and methods of using pyridonyl guanidine compounds as therapeutic agents to treat medical disorders, such as an immune disorder, inflammatory condition, or cancer.
    Type: Application
    Filed: December 8, 2011
    Publication date: February 20, 2014
    Applicant: Lycera Corporation
    Inventors: Gary D. Glick, Alexander R. Hurd, Matthew N. Mattson, Clarke B. Taylor, Chad A. Van Huis